Objective: Homeostatic synaptic plasticity (HSP) serves as a gain control mechanism at central nervous system (CNS) synapses, including those between the dentate gyrus (DG) and CA3. Improper circuit control of DG-CA3 synapses is hypothesized to underlie epileptogenesis. Here, we sought to (1) identify compounds that preferentially modulate DG-CA3 synapses in primary neuronal culture and (2) determine if these compounds would delay or prevent epileptogenesis in vivo. Methods: We previously developed and validated an in vitro assay to visualize the behavior of DG-CA3 synapses and predict functional changes. We used this "synapse-on-chip" assay (quantification of synapse size, number, and type using immunocytochemical markers) to dissect the mechanisms of HSP at DG-CA3 synapses. Using chemogenetic constructs and pharmacological agents we determined the signaling cascades necessary for gain control at DG-CA3 synapses. Finally, we tested the implicated cascades (using kappa opioid receptor (OR) agonists and antagonists) in two models of epileptogenesis: electrical amygdala kindling in the mouse and chemical (pentylenetetrazole) kindling in the rat. Results: In vitro, synapses between DG mossy fibers (MFs) and CA3 neurons are the primary homeostatic responders during sustained periods of activity change. Kappa OR signaling is both necessary and sufficient for the homeostatic elaboration of DG-CA3 synapses, induced by presynaptic DG activity levels. Blocking kappa OR signaling in vivo attenuates the development of seizures in both mouse and rat models of epilepsy. 
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| INTRODUCTION
The most common form of adult acquired epilepsy-temporal lobe epilepsy (TLE)-is characterized by seizures originating in the temporal lobe, including hippocampus, amygdala, and temporal cortex. 1 Improper "gating" of input to the hippocampus, in particular the recurrent networks of the CA3 region, has been implicated extensively in temporal lobe seizures, 2, 3 particularly in medial TLE (mTLE). [4] [5] [6] In the healthy hippocampus, input to the CA3 region arrives predominantly from the dentate gyrus (DG) via mossy fibers (MFs), the enormous specialized axon terminals of DG granule cells. 7 DG neurons heavily gate input to CA3 both directly and via hilar interneurons. Several hypotheses have been presented to explain the loss of dentate-CA3 gating in TLE. Major theories include the selective loss of hilar interneurons and the pathologic reorganization of MF axons. [8] [9] [10] A more recent hypothesis is that a failure of circuit-level closed-loop control underlies hippocampal epileptogenesis. Neurons in several areas of the nervous system recalibrate their connections in response to overall network activity: chronic inactivity often increases excitatory synaptic strength, whereas chronic hyperactivity decreases it. [11] [12] [13] These compensatory negative-feedback mechanisms, collectively termed homeostatic synaptic plasticity (HSP), are thought to maintain appropriate levels of neuronal output, providing stability within dynamic neural networks. 14, 15 However, it has been difficult to test this idea, as many factors involved in homeostatic plasticity are also important in general synaptic function.
Recently we showed that homeostatic compensation in hippocampus occurs preferentially at synapses between dentate gyrus MFs and the proximal dendrites of CA3 neurons. 16 Other excitatory hippocampal synapses were unchanged, both in vitro and in vivo, as assayed through structural and functional measures. 16 The large, complex MF-CA3 synapse has therefore been suggested to act as a hippocampal "gain control," adjusting the bandwidth of information entering the hippocampus. 17 It has been hypothesized that improper gain control at the proposed MF-CA3 checkpoint may lead to excessive hippocampal inputs and seizures. 18 We have previously developed and validated an in vitro assay for MF-CA3 synapses. 16 Here, we used this "synapse-on-chip" approach to screen for compounds capable of selectively altering MF-CA3 synapses in vitro. We then proposed testing of these compounds in vivo to determine whether improper homeostatic calibration at MF-CA3 synapses was responsible for the emergence of mTLE.
| METHODS
All procedures were performed in accordance with the regulations of Georgetown University's Institutional Animal Care and Use Committee.
| Primary hippocampal cultures and in vitro pharmacology
Hippocampal neurons were prepared from E19 rat embryos as described 19 (Data S1) and analyzed at >21 days in vitro (DIV). Neurons were treated for 24-48 hours, as indicated with drugs from the following sources. Concentrations in bold were selected after dose-response tests for efficacy and toxicity. Tetrodotoxin (or TTX; 1 lmol/L) or picrotoxin (or PTX; 100 lmol/L), both from Sigma (St. Louis, MO, USA), were used to suppress neuronal firing (TTX) and increase activity (PTX), respectively. Opioid receptor (OR)-targeting drugs were obtained from Tocris (Bristol, United Kingdom). We tested the mu receptor agonist, DAMGO (100 nmol/L, 1 lmol/L, 10 lmol/L), the mu receptor antagonist CTOP (50 nmol/L, 500 nmol/L, 5 lmol/L), the delta receptor agonist DPDPE (100 nmol/L, 1 lmol/L, 10 lmol/L), the delta receptor antagonist ICI
(1 lmol/L, 10 lmol/L, 100 lmol/L). We also tested the broad-spectrum OR antagonist, naloxone (1 lmol/L, 10 lmol/L, 100 lmol/L) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). TTX (1 mmol/L) and naloxone (100 mmol/L) stock solutions were prepared in distilled water. PTX was freshly prepared in 0.1 mol/L NaOH. Stock solutions of OR drugs were prepared in saline. Drugs were diluted in Neurobasal media to the final concentration from stock solutions.
| Immunocytochemistry
Neurons were stained using the following primary antibodies at the indicated dilutions: PSD-95 (NeuroMab, Davis, CA, USA) (1:200-400), SPO (Synaptic Systems, Goettingen, Germany) (1:400), MAP2 (Abcam, Cambridge, United Kingdom) (1:200), and CTIP2 (Abcam) (1:200-1000). See Data S1 for full details.
| Immunohistochemistry
After chemical kindling, brains were stained for synaptoporin (SPO; Figure S5D ). See Data S1 for full details.
| Image acquisition
Fluorescent microscopy: Images were acquired using a Zeiss Axiovert 200M epifluorescent microscope and analyzed using MetaMorph software (Molecular Devices, Sunnyvale, CA, USA). Images were obtained of neurons with separable dendritic arbors. Only dendrites that could be unambiguously traced for at least 100 lm from the soma were used for analysis. For computation of immunofluorescence intensity as a function of distance, dendrites were divided into 20 lm segments, starting from the cell body. 16 The strongest 3 dendrites on each neuron were traced, and 20 lm regions centered on the dendrite were automatically generated. Postsynaptic density (PSD)-95 or SPO immunoreactivity was quantified as total integrated intensity per 20 lm region after thresholding. Cellular averages were obtained and subsequently pooled into group averages. Immunoreactivity is expressed per 20 lm region or in proximal (<20 lm) and distal (>80 lm) subregions. Stimulated emission depletion (STED) microscopy: See Data S1 for full details.
| Cell type identification
For cell type identification ( Figure 1A ), we used established criteria that we and others have developed 16, 20 : DG neurons are immunopositive for chicken ovalbumin upstream promoter transcription factor-interacting protein 1 (CTIP2) and have small oblong cell bodies with 2-3 primary neurites, along with MF axon terminals enriched for the vesicle-associated protein SPO. 20, 21 CA1 neurons are immunopositive for CTIP2 and have large somata with >7 primary neurites. CA3 neurons are CTIP2 negative and have proximal dendrites with excitatory synapses that closely contact SPO-positive MF terminals ( Figure S1 ). Details of neurite number, thickness, and other morphologic/biochemical/electrophysiologic properties of these cells types can be found in Lee et al. 16 .
For DG-CA3 synapse identification (Figures 2A and S1 ), we identified green fluorescence protein (GFP)-filled DG neurons based on appearance (described earlier, Figure 1A ) and traced the GFP-filled axons to terminals on proximal (<40 lm) dendrites of a GFP-negative target cell. DG terminals are larger than normal synaptic terminals and show preference for proximal dendrites, making them easy to trace unambiguously. In our experience, almost 80% of SPO-positive DG terminals target CA3 neurons. 16 We imaged GFPfilled presynaptic terminals and then captured the SPO content of the presynaptic terminals and the PSD-95 content of the nearby synapses blindly (using preestablished channel settings, Figure 2A , top row). Analysis of DG-CA3 synapses was done by placing circles of equal size around GFP-filled terminals within the proximal (<40 lm) portion of a CA3 dendrite and quantifying the bouton volume (GFP area), amount of presynaptic SPO, and amount of PSD-95 staining within that area ( Figure 2A , bottom row).
| DREADD transfection and analysis
Cultured neurons (>21 DIV) were sparsely transfected using Lipofectamine 2000 (Invitrogen Thermo Fisher, Waltham, MA, USA) with GFP alone (AAV5-CaMKIIa-HA-EGFP) or transfected with one of the following GFP-containing DREADD (Designer Receptors Exclusively Activated by Designer Drugs) constructs: Gq-DREADD (AAV5-CaMKIIa-HA-hM3D(Gq)-IRES-mCitrine), Gi-DREADD (AAV5-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine), or Gs-DREADD (AAV5-CaMKIIa-HA-rM3D(Gs)-IRES-mCitrine), all from UNC Vector Core (Chapel Hill, NC, USA). Although these are adeno-associated virus (AAV) vectors, we used transfection to obtain sparse expression of the DREADDs (~0.05% efficiency). After 48 hours of transfection, neurons were incubated in the absence or presence of clozapine N-oxide (CNO) (1 or 10 lmol/L; Enzo Life Sciences, Farmingdale, NY, USA) for 24-48 hours and then processed for immunocytochemistry. Randomly transfected cells were classified as DG neurons as described in the preceding section. See Data S1 for full details.
| Electrical kindling
Adult male C57Bl/6J mice were obtained from Charles River (Boston, MA, USA), and a bipolar stimulating electrode was stereotaxically implanted into their left basolateral amygdalae. We waited at least 14 days after surgery to allow normalization of seizure threshold, 22 after which mice were kindled daily at an individually determined afterdischarge (AD) threshold. ADs were monitored electrographically, and the behavior was manually recorded by an observer blinded to the experimental condition. Seizures were scored using a modified Racine score (Table S3) . Kindling continued daily until mice experienced 4, stage 5 seizures, a status defined as fully kindled. See Data S1 for full details.
| Chemoconvulsant kindling
Adult male Sprague-Dawley rats were acquired from Charles River. Rats were treated every 2 days with pentylenetetrazole (PTZ; 20-22.5 mg/kg, ip). This subconvulsant dose was selected to maximize sensitization to PTZ, as single injections of 20-22.5 mg/kg rarely evoked generalized seizures. 23 Rats were observed for 15-30 minutes following injection of chemoconvulsant, and behavior was quantitatively scored using a modified Racine scale (Table S3 ). See Data S1 for full details.
| In vivo opioid receptor pharmacology
Each kindling session, animals (mice or rats) received intraperitoneal injections of either saline, U50488 (5 mg/ kg; Tocris) or norBNI (5 mg/kg; Tocris), approximately 1.5 hours after kindling. Drugs were prepared fresh in sterile saline. U50488 at higher doses (10 mg/kg) and other kappa OR agonists 24 are known to acutely mitigate chemoconvulsant-induced seizures when administered <2 hours before chemoconvulsant injection. [25] [26] [27] Conversely, norBNI (10 mg/kg) 24 and other kappa OR antagonists 26 are known to block the effects of U50488. We selected drug concentrations 50% below the effective doses shown to acutely alter seizure severity and/or duration. We also administered drugs after daily kindling to reduce drug interference with kindling per se. With this dosing scheme, U50488 (half-life 2.60 hours) 28 would not be present appreciably during subsequent electrical kindling sessions, although residual norBNI (half-life 18.94 hours) 29 may remain.
| Statistics
Data were analyzed using Prism (GraphPad Software, La Jolla, CA, USA 
| RESULTS
Various cell types in the nervous system recalibrate in response to sustained changes in overall activity, most commonly through compensatory changes in synaptic strength: prolonged inactivity increases excitatory synaptic strength, whereas prolonged hyperactivity decreases it.
11,12
We have previously observed that excitatory synapses of excitatory hippocampal neurons do not respond uniformly to activity changes. Both in vitro and in vivo, synapses between MFs of DG granule cells and proximal dendrites of CA3 neurons demonstrate large bidirectional compensations to activity changes, whereas other synapses do not. 16 Remarkably, the MF-CA3 synapse is recapitulated faithfully in dissociated hippocampal neuron cultures: in vitro MF-CA3 connections demonstrate the same striking size, unique morphology, proximal dendritic distribution, molecular components, pharmacologic sensitivity, and activity responsiveness as the in vivo synapse. 16, 20 Here, we use our validated "synapse-on-chip" approach to dissect the mechanisms of regulation of the DG-CA3 proximal synapses (hereafter MF-CA3 synapses) in vitro, screen drugs that act preferentially on this synapse, and predict in vivo drug effects.
| Homeostatic elaboration of DG-CA3
proximal synapses in vitro is determined by presynaptic activity
The various types of excitatory hippocampal neurons (DG granule and CA1/CA3 pyramidal cells) can be identified in dissociated cultures using a combination of previously established criteria 16, 20 including cell body size, number of neurites, and expression of the marker protein CTIP2 ( Figure 1D ,G) neurons did not demonstrate compensatory postsynaptic strengthening (N = 20 neurons/condition, 3 dendrites/neuron; ***P < .001 vs NT). Furthermore, the increases in accumulation of postsynaptic proteins were confined to the proximal (<40 lm) portion of CA3 dendrites ( Figure 1D , G). CA3 proximal dendrites are the territory of the large MF axon terminal boutons of DG granule cells (Figure 2A) ; even in vitro, DG axons show a pronounced preference for proximal dendrites of their targets ( Figure S1B , Figures 2A, and S2 ). DG terminals are also extremely large and readily identifiable by immunocytochemistry because, unlike other presynaptic terminals, these compartments are enriched in the vesicle-associated protein synaptoporin (or SPO) 20, 21 ( Figure S1E ). We verified the presynaptic vesicular localization of SPO using superresolution microscopy ( Figure S2 ). SPO was the presynaptic scaffolding protein, Bassoon, and showed strong co-localization with vGlut1, found on vesicles containing the excitatory neurotransmitter glutamate (Figure S2D -E,G-H). SPO puncta were directly opposed to PSD-95 puncta on proximal dendrites, as observed previously ( Figure S2B -C,F). 16 Presynaptic SPO accumulation is necessary and sufficient for the functional homeostatic strengthening of DG-CA3 proximal synapses, 16 suggesting that presynaptic mechanisms may drive compensatory changes at this synapse. To determine the locus of compensation, we transfected neurons with DREADDs, G protein-coupled receptors engineered to be activated exclusively by an exogenous, otherwise inert agent, clozapine N-oxide (or CNO). 31,32 CNO silences cells expressing G i -DREADD, activates those expressing G q -DREADD, and increases cyclic AMP (cAMP) levels via G s -DREADD, 31, 32 while leaving untransfected neurons unaffected. We examined the consequences of DREADD expression on DG neurons and their postsynaptic targets. We identified GFP-positive, DREADD-transfected DG granule cells ( Figures S1 and 2A ) and traced their GFP-positive axons to their untransfected CA3 targets. We then quantified the area and SPO content of the bouton, as well as PSD-95 accumulation in nearby proximal dendrites (Figure 2A) . Chronic inactivation of G i -DREADD-expressing DG neurons provoked a large (~250%) increase in presynaptic bouton size (in lm 2 : G i +NT 2.8 AE 0.6, G i +CNO 6.9 AE 0. G i +NT 64.9 AE 17.1, G i +CNO 207.2 AE 73.9) (Figure 2B , E). In contrast, neither GFP transfection alone nor Gq-/Gs-DREADD activation had significant effects on bouton size, SPO accumulation, or PSD-95 accumulation (Figure 2C -E; Figure S3 ). These results suggest that presynaptic mechanisms drive the concerted pre-and postsynaptic expansion of DG-CA3 proximal synapses.
| Opioid receptor signaling collectively constrains DG-CA3 synapses
Suppression of activity in presynaptic DG neurons induced DG-CA3 proximal synapse elaboration in vitro. We next aimed to determine the signaling mechanisms responsible. Unlike other presynaptic terminals in the hippocampus, MF terminals are highly enriched with endogenous opioid neuropeptides as well as mu, kappa, and delta opioid receptors (ORs). [33] [34] [35] [36] [37] Of interest, MF opioid content-like MF synaptic strength-is inversely regulated by activity. Under basal conditions, MFs contain high levels of dynorphin and low levels of enkephalin. 35, 37 However, following hilar lesion-induced seizures, MF enkephalin levels are elevated, while dynorphin is depleted. Figures 3A,B ,D and S4) (TTX: 338.2 AE 47.9% of NT) along proximal dendrites of CA3 neurons. Hyperactivity had no effect on SPO levels (PTX: 104.6 AE 21.5% of NT, PTX+1 lmol/L naloxone: 136.5 AE 15.1%), and decreased proximal dendritic PSD-95 accumulation (PTX: 34.1 AE 4.7% of NT) ( Figure 3A-C) , as has been observed previously. 16 No significant differences in PSD-95 levels were observed in distal dendrites under any condition (TTX: 136.0 AE 15.3% of NT; PTX: 87.6 AE 10.0% of NT; P > .05) ( Figures 3A-C and S4 ), supporting previous findings that homeostatic synaptic compensations in vitro occur preferentially at proximal DG-CA3 synapses. 16, 30 Blockade of ORs with naloxone caused a dose-dependent increase in proximal dendritic PSD-95 accumulation in CA3 neurons (1 lmol/L naloxone: 94.1 AE 10.9% of NT; 100 lmol/L naloxone: 261.5 AE 35.0% of NT; P < .001, Figure 3A ,B) and presynaptic SPO accumulation in opposing terminals (1 lmol/L naloxone: 78.5 AE 25.3% of NT; 100 lmol/L naloxone: 418.5 AE 60.2% of NT, Figure 3A,C) . Concurrent treatment with TTX and naloxone caused no additional increase in PSD-95 upregulation over TTX or naloxone treatment alone (TTX+100 lmol/L naloxone: 239.7 AE 23.9% of NT), suggesting that the 2 pathways may be mechanistically overlapping. Naloxone did, however, enhance the inactivity-driven accumulation of SPO (TTX: 338.2 AE 47.9% of NT; TTX + naloxone: incubated for 24 h under normal activity conditions (NT), hyperactivity (PTX) or inactivity (TTX) in the absence (top) or presence (bottom) of the broad-spectrum OR antagonist, naloxone. DG axon terminals and excitatory synapses were visualized with SPO (blue) and PSD-95 (red), respectively. B, Representative proximal (<20 lm from soma) and distal (>80 lm) CA3 dendrites immunostained with SPO (blue) and PSD-95 (red). C, Quantification of PSD-95 immunoreactivity in proximal (<20 lm from soma) and distal (>80 lm) CA3 dendrites. **P < .01, ***P < .001, 1-way ANOVA and post hoc Dunnett's comparison vs NT. NS (P > .05) vs conditions indicated. D, Quantification of SPO accumulation in presynaptic DG terminals opposite proximal (<20 lm from soma) and distal (>80 lm) CA3 dendrites. **P < .01, ***P < .001, ++P < .01, 1-way ANOVA and post hoc Bonferroni multiple comparison test. Data are expressed as mean AE SEM from neuronal averages (n = 10-20 neurons/group, 3 dendrites/neuron). Scale bar, 20 lm
that had no effect alone were sufficient to counter the effects of PTX treatment on proximal PSD-95 ( Figure 3A,B) Figure 4A,B,D) . Conversely, chronic blockade of kappa ORs with the antagonist norBNI decreased proximal PSD-95 (1 lmol/L norBNI: 72.0 AE 8.9; P < .05 vs NT) ( Figure 4E ). These results suggest that kappa OR signaling is sufficient to induce transsynaptic DG-CA3 synapse elaboration.
In contrast, activation of mu ORs with the agonist DAMGO caused a mild dose-dependent decrease in presynaptic SPO (100 nmol/L DAMGO: 93.6 AE 20.0% of NT; 1 lmol/L DAMGO: 58.1 AE 9.6) ( Figure 4A -C) and proximal PSD-95 (100 nmol/L DAMGO: 127.6 AE 22.5% of NT; 1 lmol/L DAMGO: 63.8 AE 12.5) (Figure 4D ), although these did not reach significance. Conversely, mu OR blockade with the antagonist CTOP increased proximal PSD-95 (50 nmol/L CTOP: 304.2 AE 33.7% of NT; P < .001 vs NT) ( Figure 4E ). These results suggest that mu OR signaling negatively constrains DG-CA3 synapses.
Activation of delta ORs with DPDPE did not significantly alter SPO expression (1 lmol/L DPDPE: 77.1 AE 18.2% of NT; 10 lmol/L DPDPE: 65.7 AE 9.1) ( Figure 4A-C) or proximal PSD-95 levels (1 lmol/L DPDPE: 108.9 AE 13.4% of NT; 10 lmol/L DPDPE: 122.8 AE 13.1) ( Figure 4D These results suggest that mu OR signaling (and possibly delta OR signaling) constrains DG-CA3 synapses. Loss of delta/mu signaling allows DG-CA3 synaptic elaboration, likely accounting for the effects of naloxone (Figure 3) . In contrast, kappa OR signaling is sufficient to induce the elaboration of DG-CA3 synapses. Under no condition did we observe significant changes in distal PSD-95 levels (P = .274, ANOVA) ( Figures 4, 5 and S4 ). Distinct OR signaling pathways therefore bidirectionally and selectively mediates DG-CA3 plasticity in vitro.
To determine whether OR signaling is a component of the activity-dependent homeostatic adjustment of DG-CA3 synapses, we modulated the activity of mature hippocampal neurons in the presence or absence of either agonists or antagonists of the mu, delta, and kappa ORs ( Figure 5 , Table S2 ). With intact OR signaling, inactivity increased, while hyperactivity decreased, proximal dendritic PSD-95 in CA3 neurons ( Figure 5A ) (TTX: 266.0 AE 30.1% of NT; PTX: 42.0 AE 13.9% of NT; P < .0001) and SPO along proximal dendrites ( Figure 5I ). To better visualize activity-dependent responses, regardless of basal drug effects, we plotted the net changes in Figure 5E -L.
We then determined whether OR signaling influenced the ability to respond to inactivity and/or hyperactivity. As before, manipulation of mu or delta OR signaling had basal effects on DG-CA3 synapses (NT columns in Figure 5B,C,F,G) . However, these basal drug effects did not prevent homeostatic compensations. In the presence of mu OR agonist or antagonist ( Figure 5B,F) , TTX still induced significant increases in PSD-95 levels (DAMGO+TTX: 130.6% increase over DAMGO, CTOP+TTX: 74.6% increase over CTOP; P < .001, Bonferroni test vs CTOP alone) (orange bars in Figure 5F ), whereas PTX decreased PSD-95 levels ( Figure 5B , and dark blue bars in Figure 5F ). Manipulation of delta OR signaling gave largely similar results ( Figure 5C ,G). These observations suggest that homeostatic synaptic elaboration in response to inactivity (orange bars in Figure 5E -G show net positive change) and contraction in response to hyperactivity (dark blue bars) are both intact in the presence or absence of mu and delta OR signaling.
The kappa OR agonist U50488 again increased proximal PSD-95 and SPO levels but, in marked contrast to our findings with mu and delta targeted drugs, this occluded the effects of TTX (U50488: 224.3 AE 29.5% of NT; U50488+TTX: 198.5 AE 30.5% of NT) ( Figure 5D ,H,L). These results suggest that TTX-induced homeostatic upregulation proceeds through kappa OR signaling. Indeed, the kappa OR antagonist norBNI blocked inactivity-induced homeostatic upregulation of PSD-95 (norBNI: 111.6 AE 13.3% of NT; norBNI + TTX: 126.4 AE 25.3% of NT) ( Figure 5D,H) . Taken together, these data reveal that kappa OR signaling is necessary and sufficient to mediate the homeostatic elaboration of DG-CA3 proximal synapses in response to inactivity. It has been hypothesized that MF-CA3 synapses serve as gain control for hippocampal circuits, regulating the bandwidth of information arriving from the cortex via the dentate gyrus. 17 Inappropriate gain control at MF-CA3 synapses has been suggested to underlie temporal lobe epileptogenesis. 18 If this were true, blocking homeostatic elaboration of DG synapses would prevent epileptogenesis, while promoting homeostatic elaboration would exacerbate it. Given the effects of kappa OR signaling on DG-CA3 synaptic homeostasis in vitro, we hypothesized that these drugs would bidirectionally modulate epileptogenesis in vivo. We tested this hypothesis using the amygdala kindling model, which generates increasingly severe temporal lobe seizures. [38] [39] [40] Each day, mice were kindled, followed by injections of saline, the kappa OR agonist U50488 (5 mg/ kg/d, ip), or the kappa OR antagonist norBNI (5 mg/kg/d, ip) ( Figure 6B ). The kappa OR agonist U50488 and antagonist norBNI are known to have acute anti-and proconvulsant effects, respectively, when administered before injection of a chemoconvulsant. 26, 27, 41 However, the action of these drugs at DG-CA3 synapses in vitro predicts the opposite effect of the drugs on the gradual emergence of seizures if chronically administered during epileptogenesis. Because we are interested in long-term homeostatic adaptations induced by the drugs, not acute effects, drugs were administered after daily electrical stimulation and at doses below those shown to have acute effects on seizure severity (see Methods). Administration of the kappa OR agonist, U50488 (5 mg/kg/d) resulted in faster kindling compared to control animals ( Figure 6A,B) . Conversely, mice receiving daily injections of the kappa OR antagonist norBNI (5 mg/kg/d) kindled significantly more slowly ( Figure 6A ,B) and less severely ( Figure 6D ). NorBNI increased, whereas U50488 decreased, both time to first generalized seizure (Figure 6A ) (median time to first stage 5 seizure (in days): NT 10, norBNI 15, U50488 9; P = .009, Mantel-Cox test of survival curves) and time to full kindling ( Figure 6B ) (median time to 4 stage 5 seizures [in days]: NT 16, norBNI >21, U50488 11; P = .008, Mantel-Cox test). Indeed, after the 21-day protocol, norBNI animals remained incompletely kindled (fully kindled by day 21: NT 7/7 animals, norBNI 3/8, U50488 5/5), and some norBNI mice failed to reach even a single stage 5 seizure ( Figure 6A ). NorBNI decreased both seizure duration ( Figure 6C ) and severity ( Figure 6D ), whereas U50488 increased these parameters (seizure duration: P < .001; seizure severity: P = .027 ANOVA).
We observed no significant difference in AD duration at the start of the study (mean AE SD [in seconds]: NT 7.8 AE 9.8, norBNI 10.1 AE 8.6, U50488 13.3 AE 11.5; P = .226, Kruskal-Wallis test), suggesting that intrinsic excitability did not differ between groups at baseline. We also observed no significant changes in AD threshold (ADT) (P = .170, Kruskal-Wallis test), a measure of kindling stimulation efficacy, over the course of the study. Finally,, we observed no strong relationship between average seizure severity and initial or final ADT (Figure 6E,F) . Stimulation intensity was therefore not considered a factor in the findings.
The in vivo effects of chronic kappa OR treatment predicted by our "synapse-on-chip" assay are precisely the opposite pattern that has been reported in response to acute, preseizure administration of these drugs. These findings demonstrate that the chronic norBNI treatment paradigm, which prevents DG-CA3 elaboration in vitro, suppresses the emergence of temporal lobe seizures in vivo.
To generalize our findings to another species and seizure model, we investigated chemically induced kindling in rats ( Figures 6G-I and S5 ). We selected pentylenetetrazole (PTZ), a GABA A receptor antagonist, as the chemoconvulsant, since PTZ kindling is a widely used animal model for screening novel antiepileptic compounds. 42 Rats received an initially subconvulsant dose of PTZ (20-22.5 mg/kg, ip) 23 every other day for 11 sessions ( Figure 6G ). After each kindling session, rats were given either saline (NT) or norBNI (5 mg/kg, ip, a concentration 50% below that shown to acutely affect seizure severity and EEG patterns in rats). Delivery of norBNI was delayed 1-3 hours after PTZ to minimize acute interaction effects with the chemoconvulsant (schematic in Figure 6G ). Saline-treated rats developed progressively stronger behavioral seizures over the course of the kindling sessions (main effect of kindling day, P < .0001; aligned-rank-transform test) ( Figure 6G ). In contrast, the norBNI-treated group displayed essentially no seizures ( Figure 6G ) (main effect of treatment, P = .0059; treatment by day interaction effect, P < .0001; aligned-rank-transform test). On the last kindling day, we observed a significant difference between groups in mean seizure severity (P = .015, Mann-Whitney test) (Figure 6H ) and in maximal seizure severity scores (P = .0043, Mann-Whitney test) ( Figure 6I ). We also observed a significant difference in the proportion of animals displaying any limbic motor response (score of 2 or greater): the majority (5/6) of saline-treated, but no norBNI-treated, animals attained this response (P = .0152, Fisher's exact test).
To determine if norBNI's impact on chemoconvulsant kindling was due to acute (not the intended chronic) effects, we pretreated a group of rats (n = 6) with norBNI or saline 46.5 hours prior to a single challenge dose of PTZ; this timing was selected to match the interval between drug treatment and PTZ administration in our chronic studies. We found that both groups displayed a median seizure severity of 0.5, and did not differ significantly from each other (Mann-Whitney, U = 16, P = .999). Thus acute effects of norBNI do not account for the antiepileptogenic effects we demonstrate here.
To assess if norBNI-dependent changes in seizure progression correlated with alterations in SPO levels in the brains of protected animals, we repeated the treatment in an independent cohort of saline or norBNI-treated animals (n = 5/group). We again observed that norBNI was protective against epileptogenesis: norBNI seizure burden was significantly less throughout the study (Figure S5A-C) . However, in these animals, we observed no significant changes in SPO expression in the granule cell layer of the dentate gyrus ( Figure S5D-H) . CA3 expression of SPO was mildly correlated with seizure burden (R 2 = 0.256), whereas hilar SPO expression was moderately correlated with seizure burden (R 2 = 0.530) ( Figure S5I -K).
Taken together, we concluded that the kappa OR antagonist is capable of suppressing seizure development in vivo in 2 rodent species and 2 epilepsy paradigms. The kappa OR agonist U-50488 has the opposite effect, exacerbating seizure progression. The direction of action of the kappa OR drugs during chronic treatment while seizures emerge is opposite their reported acute effects. However, the direction of action of the kappa OR drugs is predicted by their chronic effects at DG-CA3 synapses in vitro, as determined by our "synapse-on-chip" assay. We therefore suggest that DG-CA3 synapse elaboration, a critical component of hippocampal homeostatic plasticity, which is mediated by kappa OR signaling, is a necessary component of temporal lobe epileptogenesis and a viable target for therapeutic interventions.
| DISCUSSION
In this study, we investigated whether inappropriate hippocampal gain control could contribute to epileptogenesis and whether harnessing endogenous neuronal calibration mechanisms could inhibit development of seizures. Our previous studies implicated the MF-CA3 synapse as a major mediator of homeostatic compensation in the hippocampus. Here, we found that presynaptic activity of DG granule cells dictates coordinated pre-and postsynaptic homeostatic changes across DG-CA3 proximal synapses in vitro. Because DG axon terminals are highly and distinctively enriched with endogenous opioid neuropeptides, we examined the role of ORs in HSP. The pharmacologic experiments using complete blockade of ORs by naloxone suggested that ORs collectively restrain DG-CA3 synapses. Of interest, distinct OR types appear to act in opposing ways: mu and delta ORs basally constrain DG-CA3 synapses, whereas kappa ORs promote their elaboration (Table S2) . Moreover, although mu and delta OR signaling appear dispensable for homeostatic adaptation, kappa OR signaling is both necessary and sufficient for homeostatic growth of DG-CA3 synapses in vitro (Table S2) .
Based on these properties, we suggest that presynaptic opioid neuropeptides are major coordinators of homeostatic plasticity at MF-CA3 synapses, providing closed-loop activity-dependent control of CA3 networks 18 ( Figure S6 ).
A common strategy in engineered closed-loop systems is proportional-integral control: the appropriate compensation to a deviation from the expected course is calculated based on both the current magnitude (proportional) and overall persistence of the problem (integral, ie, cumulative deviation over time). We propose that presynaptic opioid peptides could provide such proportional-integral control. The relative accumulation of the opioid peptides would encode the activity history of DG neurons, whereas the release of the opioids would encode the current activity. Opioid signaling could thus coordinate transsynaptic changes at the MF-CA3 synaptic "gate" that are appropriate to the duration and magnitude of a change in neural activity. Upregulation of this gate in principle could involve increased number/size of synapses or the recruitment of synaptic components including PSD-95. The integrity of the opioid signaling system may therefore be crucial to maintaining the DG "gate" to the CA3 network ( Figure S6 ). We hypothesized that improper strengthening of MF-CA3 synapses in vivo promotes the development of seizures. We thus sought to exert a "homeostatic brake," combating epileptogenesis by weakening these synapses via their endogenous control mechanism. We propose that kappa OR signaling regulates the homeostatic gain control program at MF-CA3 synapses. Without kappa OR signaling, MF-CA3 synapses cannot undergo inactivity-induced expansion. This expansion may contribute to epileptogenesis, and therefore block the runaway elaboration of MF-CA3 synapses would be protective. Mu and delta antagonists, like the kappa agonist U50488, act on MF-CA3 synapses but promote elaboration in vitro. We would F I G U R E 6 Chronic blockade of kappa OR signaling counteracts epileptogenesis in mice and rats. A-F, Adult male mice (N = 7 NT, 8 norBNI, 5 U50488) were kindled once daily and seizure behavior was visually scored in blinded manner using a modified Racine scale (Table S3) (Table S3) . Approximately 1-3 h after each kindling, mice received intraperitoneal injections of saline or kappa OR antagonist norBNI (5 mg/kg). (G) Median seizure severity per group for each kindling session (N = 6 per group; **P < .001, treatment effect, aligned rank transform test). Essentially no seizure behavior was observed in norBNI animals. (H) Mean seizure score AE SD overlaid with individual animal scores on the last day of kindling (Mann-Whitney; *P = .015). (I) Mean and individual maximum seizure score attained during kindling (Mann-Whitney; **P = .0043) therefore expect chronic treatment with mu and delta antagonists to exacerbate seizure progression, similar to U50488. These results suggested kappa OR antagonists would be the most useful for our in vivo pharmacology studies. Indeed, we showed that kappa OR signaling bidirectionally alters the emergence of severe seizures in the mouse electrical kindling model, and that suppression of kappa ORs dramatically inhibited chemical kindling in rats. These effects are generally consistent with the in vitro finding that kappa OR activity is necessary and sufficient for DG-CA3 synapse homeostatic upregulation. An interesting paradox is that the effects of kappa signaling observed here during the emergence of epilepsy are opposite to those expected from the acute in vivo effects of U50488 and norBNI on chemically and electrically induced seizures. Acute pretreatment with norBNI is known to be proconvulsant, whereas acute U50488 is anticonvulsant. 26, 27, 41 We observed the opposite effects of the drugs when chronically administered after seizures during kindling. Moreover, with the dose and timing we employed, we observed no acute effects of the drugs on seizures in control experiments. We therefore do not attribute the effects of chronic drug administration to acute action, or to accumulation or residual presence of the drugs, but rather to engagement of the homeostatic negative feedback mechanism that acts counter to the applied acute manipulation. We propose that repetitive, low-level administration of norBNI, which blocks the elaboration of MF-CA3 synapses in vitro, prevents the maladaptive elaboration of MF-CA3 synapses in vivo, thereby slowing or arresting seizure progression ( Figure S6 ). Conversely, chronic administration of U50488 mimics the homeostatic expansion of MF-CA3 synapses, thereby exacerbating seizure progression. These effects contrast with a previous report that prodynorphin knockout mice display accelerated kindling. 26 Dynorphins are high-affinity agonists for kappa OR. However, developmental compensation or cross-reactivities of various dynorphin peptides to different ORs may obscure the interpretation of these data. Moreover, prodynorphin knockout mice (which have a developmental depletion of this peptide) display decreased seizure threshold, and thus kindling stimulation may be more severe in the knockouts than wild-type controls, influencing the rate of kindling. By contrast, our pulsatile blockade of kappa OR avoids effects on acute seizures and rather selectively and transiently decreases kappa OR signaling in the postseizure period. The dissociation between the genetic studies and our present findings may underscore the importance of a temporal window for intervention after an epileptogenic insult in defining the net effect.
The classical opioid receptors are G protein-coupled receptors that all link to G ai small GTPases, leading to various well-established effects such as inhibition of cAMP production, activation of G protein-gated inward rectifying potassium channels, and reduction in calcium channel conductances. 43 In view of this shared G protein second messenger, how can ORs produce differential effects in homeostatic regulation of DG-CA3 synapses? ORs are known to exist in large protein complexes, and distinct scaffold protein networks may link each receptor to a specific microdomain of signaling proteins and downstream effectors. For instance, ORs bind to arrestin proteins, and different arrestin family members could underlie some of the distinct receptor effects via downstream targets including MAP kinases. 44 Furthermore, it is possible that differential receptor localization may play a role in the specific effects of kappa ORs. An attractive hypothesis is that kappa ORs are more highly enriched at the DG-CA3 synapse itself and thus have a more potent effect on this system. In this regard, the observation that Gi-DREADD could mimic the effects of kappa OR in DG neurons suggests that it is the neuronal activity state that drives homeostatic plasticity. Thus changes induced by kappa OR signaling in our studies would be caused by Gi-signaling on neuronal activity, and its putative localization at the DG-CA3 synapse. Given the nature of Gi receptor signaling, we expect that this effect may in fact be achievable with other Gi-coupled receptors as well, and we cannot exclude the possibility that mu/delta receptors may also play a role in these mechanisms in vivo. However, although other endogenous Gi receptors may have similar signaling activity, these may not be sufficiently expressed in the DG-CA3 synapse. By this model, any Gi-receptor expressed in the right location would have an analogous effect, as would any chronic activity manipulation that selectively engages homeostatic adaptation at this synapse. Indeed, this interpretation is supported by our data with Gi-DREADDs in vitro. Because the only apparent commonality between kappa OR and Gi-DREADD is the Gi-signaling cascade, it is possible that blocking kappa OR Gi-signaling would also prevent DREADD function in our assays. Future studies are needed to dissect the precise signaling cascades and expression patterns of the kappa ORs that may be involved in modulating hippocampal homeostatic plasticity and seizure progression.
The MF-CA3 synapse contains specific molecular constituents (eg, opioid peptides and synaptoporin) that are not widely or strongly expressed at other types of hippocampal synapses. Both the present study, and prior genetic ablations have globally modulated the function of the kappa OR system. Local genetic manipulation of molecular targets specifically at MF-CA3 synapses (eg, knockdown of synaptoporin or kappa ORs in MF terminals) may provide more selective manipulation of endogenous HSP mechanisms. These studies will be key to resolving the role of intrahippocampal kappa OR signaling on seizures and epileptogenesis. Although we did not find a significant change in SPO levels in the hippocampus of protected animals following norBNI treatment, it is possible that the localization of SPO is changing, rather than the total amount, or that the change is affecting only a subset of synapses, which is difficult to detect against the background of unaffected synapses. Further experiments are necessary to conclusively demonstrate that endogenous homeostatic mechanisms are responsible for epileptogenesis or its prevention. It will be important to test this approach in animal models that exhibit spontaneous seizures to determine whether this method can alter or prevent disease pathogenesis.
Although single-synapse gain control is unlikely to represent a cure for all forms of TLE, our present findings are consistent with a long-standing literature involving the "dentate gate." Transient suppression of the dentate in mice with spontaneous seizures can suppress seizure activity, whereas driving activation of the dentate can trigger seizures. 2 Here, we have proposed a synaptic mechanism for dentate gate regulation and provided evidence that systemic pharmacologic manipulation of a signaling platform enriched in the MF-CA3 pathway can bidirectionally modulate epileptogenesis. Utilizing endogenous mechanisms of homeostatic compensation may be particularly helpful, as it can be utilized after an epileptogenic perturbation, and induced on fairly slow timescales. Exploiting endogenous homeostatic mechanisms may therefore expand the timeframe for intervention after injury. This raises the possibility that intervention after insult, but before spontaneous seizures emerge, can modify disease trajectory. This feature is therapeutically attractive as treatment does not require foreknowledge of when an insult would occur, and could potentially be administered effectively even after some delay.
